Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers

References

• Anderson S, Luffer-Atlas D, Knadler MP. (2009). Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243–256.
   PubMed Web of Science ®Google Scholar
• Aoki K, Kashiwagura Y, Horie T, Sato H, Tateno C, Ozawa N, Yoshizato K. (2006). Characterization of humanized liver from chimeric mice using coumarin as a human CYP2A6 and mouse CYP2A5 probe. Drug Metab Pharmacokinet 21:277–285.
   PubMed Web of Science ®Google Scholar
• Bauer TM, Ritz R, Haberthür C, Ha HR, Hunkeler W, Sleight AJ, Scollo-Lavizzari G, Haefeli WE. (1995). Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346:145–147.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, Smith DA. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357–368.
   PubMed Web of Science ®Google Scholar
• Dresser GK, Spence JD, Bailey DG. (2000). Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41–57.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2003). Cytochromes P450, drugs, and diseases. Mol Interv 3:194–204.
   PubMedGoogle Scholar
• Guo T, Mao GF, Xia DY, Su XY, Zhao LS. (2011). Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. J Clin Pharm Ther 36:406–411.
   PubMedGoogle Scholar
• Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. (2004). In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 76:428–440.
   PubMed Web of Science ®Google Scholar
• Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–413.
   PubMed Web of Science ®Google Scholar
• Heizmann P, Eckert M, Ziegler WH. (1983). Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16 Suppl 1:43S–49S.
   Google Scholar
• Heizmann P, Ziegler WH. (1981). Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung 31:2220–2223.
   PubMed Web of Science ®Google Scholar
• Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B. (2009). In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 67:445–454.
   PubMed Web of Science ®Google Scholar
• Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S. (2008). CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:2429–2433.
   PubMed Web of Science ®Google Scholar
• Inoue T, Sugihara K, Ohshita H, Horie T, Kitamura S, Ohta S. (2009). Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153–160.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, Murakami Y, Tanaka K, Iwatsubo T, Kawamura A, Usui T. (2010). Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25:223–235.
   PubMed Web of Science ®Google Scholar
• Katoh M, Yokoi T. (2007). Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145–157.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Nitta K, Tayama Y, Tanoue C, Sugihara K, Inoue T, Horie T, Ohta S. (2008). Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:1202–1205.
   PubMed Web of Science ®Google Scholar
• Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. (1989). Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89–96.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Schuetz EG, Thummel KE. (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271–1294.
   PubMed Web of Science ®Google Scholar
• Lootens L, Meuleman P, Leroux-Roels G, Van Eenoo P. (2011). Metabolic studies with promagnon, methylclostebol and methasterone in the uPA+/+-SCID chimeric mice. J Steroid Biochem Mol Biol 127:374–381.
   PubMed Web of Science ®Google Scholar
• Martens-Lobenhoffer J, Eisenhardt S, Tröger U, Röse W, Meyer FP. (2001). The effect of anxiety and personality on the pharmacokinetics of oral midazolam. Anesth Analg 92:621–624.
   PubMedGoogle Scholar
• Okumura H, Katoh M, Sawada T, Nakajima M, Soeno Y, Yabuuchi H, Ikeda T, Tateno C, Yoshizato K, Yokoi T. (2007). Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 97:533–538.
   PubMed Web of Science ®Google Scholar
• Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. (2003). An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 73:153–158.
   PubMed Web of Science ®Google Scholar
• Schulz-Utermoehl T, Sarda S, Foster JR, Jacobsen M, Kenna JG, Morikawa Y, Salmu J, Gross G, Wilson ID. (2012). Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Xenobiotica 42:503–517.
   PubMed Web of Science ®Google Scholar
• Seo KA, Bae SK, Choi YK, Choi CS, Liu KH, Shin JG. (2010). Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos 38:2007–2013.
   PubMed Web of Science ®Google Scholar
• De Serres M, Bowers G, Boyle G, Beaumont C, Castellino S, Sigafoos J, Dave M, Roberts A, Shah V, Olson K, Patel D, Wagner D, Yeager R, Serabjit-Singh C. (2011). Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464–475.
   PubMed Web of Science ®Google Scholar
• Streetman DS, Bertino JS Jr, Nafziger AN. (2000). Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187–216.
   PubMedGoogle Scholar
• Strom SC, Davila J, Grompe M. (2010). Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 640:491–509.
   PubMedGoogle Scholar
• Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, Yoshizato K. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–912.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Kuribayashi S, Inoue T, Tateno C, Nishikura Y, Oofusa K, Harada D, Naito S, Horie T, Ohta S. (2010). Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 23:152–158.
   PubMed Web of Science ®Google Scholar
• Yoshizato K, Tateno C. (2009). In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 5:1435–1446.
   PubMed Web of Science ®Google Scholar
• Zhu B, Bush D, Doss GA, Vincent S, Franklin RB, Xu S. (2008). Characterization of 1′-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Dispos 36:331–338.
   PubMed Web of Science ®Google Scholar